Skip to Content
Søg Menu

ESMO 2025: De-eskaleret kemoterapi før vedligeholdelses-behandling med avelumab

På ESMO kongressen 2025 præsenterede Enrique Grande, MD, PhD, fra Quirónsalud Madrid, resultaterne fra DISCUS trial. Studiet belyser effekten af de-eskaleret kemoterapi før vedligeholdelsesbehandling med avelumab ved fremskreden urothelial kræft. I denne MEDtalk perspektiverer overlæge Jakob Lauritsen, Onkologisk klinik, Rigshospitalet resultaterne i en dansk kontekst.
Jakob Lauritsen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
ESMO25NBCNBrystcancer Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
ESMO25NBCNBrystcancer Play the Video 05:53
Jakob Lauritsen

ESMO 2025: Interesting New Data on the Treatment of Bladder Cancer

/ Jakob Lauritsen
ESMO25Blærecancer Play the Video 03:47
Hildur Helgadottir

ESMO 2025: Superior Outcomes With Reduced NIVO+IPI Dose in Advanced Melanoma

/ Hildur Helgadottir
ESMO25Melanom Play the Video 05:27
Katarina Puco

ESMO 2025: Precision Medicine Trial Shows Promise in Rare Cancers

/ Katarina Puco
ESMO25 Play the Video 01:56

ESMO 2025: Advancements to Improve Patient Outcomes and Quality of Life in Immunotherapy

/ Christina Ruhlmann
ESMO25 Play the Video 4:45

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
ESMO25Blærecancer Play the Video 04:57

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Jan Andreasen
ESMO25Prostatacancer

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

/ Danny Rischin
ESMO25Hudcancer Play the Video 03:46
Back to top